Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy

NCT ID: NCT07172971

Last Updated: 2025-12-24

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-02-01
• Study Completion Date: 2028-02-01

Brief Summary

This is a pharmacokinetic study (PK Study) to better understand empagliflozin dosing in pediatric Duchenne muscular dystrophy patients. Empagliflozin is currently used off-label in this population due to the mortality benefits seen in adult cardiomyopathy and heart failure. Investigators will perform PK studies in DMD patients of various ages and weights to better understand the PK profile (absorption, distribution, metabolism, excretion) and dosing to better treat Duchenne cardiomyopathy.

Detailed Description

Duchenne muscular dystrophy (DMD) is an X-linked skeletal and cardiac myopathy resulting from a defect in the gene coding for dystrophin. DMD myopathy leads to loss of ambulation, respiratory failure, cardiomyopathy (CM), and premature death. There is no cure, and while gene therapies now have approval, their cardiac effects are largely unstudied. Supportive care advances have decreased death from respiratory failure but have simultaneously unmasked the fully penetrant CM phenotype, which is now the leading cause of death in DMD.

Investigators have documented that DMD CM progresses from normal imaging to diastolic dysfunction with subtle strain abnormalities to manifest systolic dysfunction; these changes correspond pathologically with myocardial inflammation and progressive increase in myocardial fibrosis and fibrofatty infiltration. Large areas of fibrofatty replacement visible on cardiac magnetic resonance (CMR) are felt to be irreversible, meaning that for optimal benefit, therapy must begin before these changes have occurred. Guideline-directed medical therapy (GDMT) is increasingly applied in DMD CM care, but individual response to these therapies is suboptimal and often only serves to minimally delay the inevitable progression to heart failure and early death. There is a critical need for the application of new CM therapeutics in DMD.

Sodium/glucose cotransporter-2 inhibitors (SGLT2i) have resulted in mortality benefits in adult CM. The mechanism of this beneficial effect is unknown, but several factors translating to DMD suggest that SGLT2i could have potential for DMD CM: 1) improved cardiac energetics and metabolism; 2) improved mitochondrial function and reduced oxidative stress; 3) reduction in inflammation; 4) inhibition of myocardial fibrosis; 5) reduction in sarcoplasmic calcium leak; 6) improved sympathetic overdrive. While the use of SGLT2i in pediatric patients with significant LV dysfunction has become more common, there are many significant unanswered questions. PK data are limited, and many patients are dosed based on glucosuria, which is not a proven method to determine efficacy or exclude side-effects. The potential for earlier therapy in DMD, before irreversible changes, is immense; however, an understanding of appropriate dosing for children with DMD is necessary before this can be achieved.

Conditions

Duchenne Muscular Dystrophy (DMD)

Keywords

Cardiomyopathy; Heart failure; Muscular dystrophy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Dosing

At the initial stage, investigators will allocate 3 subjects to 5 mg and 3 subjects 10 mg depending on their body weight (i.e., 5 mg for children with weight les than 40 kg, 10 mg for those with greater than 40 kg).

Group Type: EXPERIMENTAL

SGLT-2 inhibitor

Intervention Type: DRUG

SGLT-2 inhibitor will be given once daily by mouth

Pharmacokinetics

In the second stage, based on the Pharmacokinetics (PK) analysis results from the initial 6 subjects divided in 5 mg and 10 mg dose groups, the next dose will be determined, for which the remaining 4 subjects will be allocated. The next dose decision will be made based on the target drug concentration levels along with the estimated PK parameters (e.g., the area under the drug concentration time curve and the maximum concentration), which correspond to adults PK and drug levels.

Group Type: EXPERIMENTAL

SGLT2 inhibitor

Intervention Type: DRUG

SGLT-2 inhibitor will be given once daily by mouth

Interventions

SGLT-2 inhibitor

SGLT-2 inhibitor will be given once daily by mouth

Intervention Type: DRUG

SGLT2 inhibitor

SGLT-2 inhibitor will be given once daily by mouth

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Clinical phenotype of DMD confirmed with muscle biopsy or genotype
• Presence of late gadolinium enhancement (LGE) imaging by CMR
• Either normal or mildly depressed systolic function (LVEF>40%)
• ≥8 years old and ≤18 years old

Exclusion Criteria

• Current investigational therapy that may affect cardiovascular function

• Additional genetic or congenital abnormality that may affect cardiovascular function or progression
• Contraindication to or inability to undergo CMR
• Symptomatic heart failure
• History of ketoacidosis or hypersensitivity to SGLT2i therapy
• Type 1 diabetes
• Renal disease or history of frequent urinary tract infections or genitourinary skin infections

• Minimum Eligible Age: 8 Years
• Maximum Eligible Age: 18 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)

NIH

Sponsor Role: collaborator

Larry W. Markham

OTHER

Sponsor Role: lead

Responsible Party

Larry W. Markham

Professor of Pediatrics

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Larry W. Markham, MD

Role: PRINCIPAL_INVESTIGATOR

Riley Children's Hospital

Locations

Riley Hospital at Indiana University Health

Indianapolis, Indiana, United States

Countries

United States

Central Contacts

Larry W Markham, MD

Role: CONTACT

Phone: 317 944-8906

Email: lwmarkha@iu.edu

Jennifer Howell, RN

Role: CONTACT

Phone: 317 944-8906

Email: jemrich@iu.edu

Other Identifiers

1R61HL180327-01

Identifier Type: NIH

Identifier Source: secondary_id

View Link

28323

Identifier Type: -

Identifier Source: org_study_id